Who invested in Black Diamond Therapeutics?
Black Diamond Therapeutics's investors include New Enterprise Associates, RA Capital Management, Perceptive Advisors, Wellington Management and Versant Ventures, and 3 more on record.

United States · Funded startup
Funding summaryUpdated 26 Oct 2026
$160Mraised across 2 rounds since 2019, from 2 sources
Each circle is a round, placed by date and sized by amount. The line above is the running total.
Source recorded
Reported by PrnewswireSEC filing: $42M sold, first sale Dec 2018
From the SEC filings it signed: 4 on the team.
On the board, as filediAlexander M. MaywegAli M. BehbahaniBradley M. BolzonGarry M. MenzelRajeev M. ShahSamarth M. Kulkarni
The busiest backers across the latest rounds. A filled square is a round they joined; a dark one, a round they led.
Black Diamond Therapeutics's investors include New Enterprise Associates, RA Capital Management, Perceptive Advisors, Wellington Management and Versant Ventures, and 3 more on record.
Black Diamond Therapeutics has raised $160M across 2 rounds since 2019.
Black Diamond Therapeutics's most recent round was an Undisclosed round of $75M in Jun 2023.
Black Diamond Therapeutics's largest round on record is $85M (Series B), in Jan 2019, led by New Enterprise Associates.
Black Diamond Therapeutics's first round on record, in Jan 2019, was backed by New Enterprise Associates, RA Capital Management and Versant Ventures and 3 others.
Black Diamond Therapeutics's latest named round is an Undisclosed round, in Jun 2023.
Black Diamond Therapeutics is based in the United States.
New Enterprise Associates led the Series B in 2019.
Search every investor by what they have actually funded, then narrow to your stage and market. Free.